The financing will support growth in Maravai's three life science segments: bioprocess impurity testing, oligonucleotide synthesis, and protein detection.
Using genetic probes and fluorescent scanning, the firm plans to market the $20 test for pathogens that cause urinary tract infections and biological warfare.
Fusion originally developed its synthetic capture probe technology for cancer gene fusion assays but is repurposing it to diagnose infectious diseases.
